Quote:

---

Since it does not involve an immune response

---

It does involve an immune response.

Quote:

---

As we've seen from longhaulers and chronic fatigue system the overactive immune response persists for years if not decades.

---

Quote:

---

have you any to add about the potential for clotting due to the debris spikes and how that might relate to leronlimab

---

TNF-a is heavily involved in clotting and leronlimab reduces it significantly. It's most likely the main factor why we haven't seen clotting problems in COVID-19 patients.

Quote:

---

The word was they are seeking a Phase 3 without a placebo group.

Without a placebo group? Might that imply that the phase 2 results were very good?

---

Is this a longhaulers trial and what drug is it? It doesn't imply phase 2 was very good. It means they're making a big mistake by not having a placebo arm. Not having a placebo arm in a trial where mortality is not an issue and comparables are completely unknown will not sit well with the FDA.

I am guessing your cut and paste was from the article below. Lead author - Paul Elias Alexander who was on the Trump coronavirus taskforce and wrote a metastudy in support of remdesivir. That article is a combination of science and pseudo-science.

https://trialsitenews.com/the-covid-19-spike-...-pathogen/